Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157485 | 1.00 | AGTR2 (0.55) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL15157487 | 1.00 | AGTR2 (0.55) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL17695745 | 0.93 | AGTR2 (0.55) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL17424354 | 0.93 | AGTR2 (0.55) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL21167841 | 0.91 | AGTR2 (0.54) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL21168165 | 0.91 | AGTR2 (0.54) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL13974155 | 0.91 | AGTR1 (0.66) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL15551208 | 0.91 | AGTR1 (0.66) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL15550328 | 0.91 | AGTR1 (0.66) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL30206864 | 0.91 | PPARG (0.59) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673274-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT GENERICS LTD (IN) | 2019-07-17 | — | — | EP | disclosed |
| WO-2016147120-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE AZILSARTAN | SMILAX LABORATORIES LIMITED (IN) | 2016-09-22 | — | — | WO | disclosed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150011774-A1 | PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011774-A1 | PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | REN, AGTR2, CYP4A11 | AGTR2 2/4885CYP3A4 57/4885ADORA3 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.